What is Zacks Research’s Forecast for CRL FY2025 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Zacks Research upped their FY2025 earnings estimates for Charles River Laboratories International in a report released on Wednesday, November 26th. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $10.20 for the year, up from their prior estimate of $10.12. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.31 EPS, Q1 2026 earnings at $2.38 EPS, Q2 2026 earnings at $2.74 EPS, FY2026 earnings at $10.68 EPS, Q1 2027 earnings at $2.42 EPS, Q2 2027 earnings at $2.67 EPS, Q3 2027 earnings at $2.95 EPS and FY2027 earnings at $11.30 EPS.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s revenue was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.59 EPS.

A number of other research firms also recently commented on CRL. Barclays lifted their target price on Charles River Laboratories International from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Robert W. Baird raised shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $178.00 to $199.00 in a report on Thursday, November 6th. Finally, Argus set a $200.00 price target on shares of Charles River Laboratories International in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $190.86.

Charles River Laboratories International Stock Down 0.4%

Charles River Laboratories International stock opened at $178.14 on Monday. The business’s 50-day simple moving average is $171.68 and its two-hundred day simple moving average is $160.30. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The company has a market cap of $8.77 billion, a PE ratio of -133.94, a PEG ratio of 4.83 and a beta of 1.53. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $203.01.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRL. Brooklyn Investment Group lifted its holdings in Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC raised its position in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at about $29,000. Rothschild Investment LLC grew its stake in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares in the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at about $31,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).